Targeting for TGF-β inhibition in glioma, including antisense oligonucleotide for TGF-β2, kinase inhibitor of type I TGF-β receptor and TGF-β antibodies, is currently at the clinical trial stage [74]. Here, TGFB1 is linked to glioma.